Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
Yuyan Tan, Peter Jenner, Shengdi Chen
Abstract
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce "OFF" time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.
Topics & Concepts
Monoamine oxidase BMonoamine oxidaseMedicineSelegilineParkinson's diseaseDiseaseMotor symptomsRasagilineMonoamine oxidase APharmacologyInternal medicineEnzymeChemistryBiochemistryParkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingNerve injury and regeneration